Development of innovative cancer treatments
“Day One Biopharma” official website
According to outside The media reported that recently, “ Day One Biopharma has received US $ 60 million in Series A financing. Investors include Canaan Partners, Atlas Venture and Access Biotechnology.
Julie Grant is the general partner of Canaan Partners. She said that in the past 20 years, the FDA has approved more than 200 treatment products for adult cancer. However, in the last 30 years, there have been fewer than 10 new drugs approved by the FDA for childhood cancer, and children are still waiting for their own targeted drug treatment. Therefore, Canaan Partners has been working with “Day One Biopharma” to solve this problem.
Day One Biopharma, located in South San Francisco, is a pharmaceutical start-up company. Dr. Samuel Blackman, co-founder and chief medical officer of the company, is a pediatric oncologist. The company works with clinical oncologists and scientists to designed to develop innovative cancer Treatment method, mainly used for Treatment Pediatric cancer, while adults alsoThis therapy can be used.
“Day One Biopharma” The first development project is DAY101, formerly known as TAK -580 is a targeted therapy for children with brain cancer. DAY101 is an oral medication, used once a week. “Day One Biopharma” is currently undergoing clinical trials to evaluate the effects of DAY101.
Samuel Blackman stated that DAY101 is a unique drug with a unique mechanism of action. It targets cancers with mutations in BRAF (this gene is located on human chromosome 7 and encodes a serine or threonine protein kinase of the RAF family), as well as cancers with BRAF wild-type fusion proteins. A large proportion of pediatric tumors are caused by BRAF wild-type fusion proteins, not by BRAF mutations.
This drug has been clinically tested in more than 250 patients and is in a trial funded by researchers. It also treats patients with recurrent glial Children with tumors were tested. “Day One Biopharma” The safety and safety of medicines will be announced this year or next Efficacy data.
“Day One Biopharma” official website
In addition to developing DAY101, “Day One Biopharma” will also use a new round of financingThe funds attract more investors to invest.
When it comes to clinical trials, children are usually ranked last, for many reasons, including outdated ways of thinking. For example, many people think that children cannot tolerate cancer drugs like adults, or think that pediatric cancer trials are too difficult.
Julie Grant stated that “Day One Biopharma” is actively looking for opportunities for cooperation to create the best products that will change the standard of pediatric cancer treatment.